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Objectives: Oral candidiasis (OC) is a frequent oral lesion in renal transplant patients (RTPs). Despite the in-
creased prevalence of OC in RTPs, no study has examined related risk factors. The aims of this study were to 
analyze the prevalence of and risk factors for OC in RTPs compared with age- and gender-matched healthy control 
group (HC) as well as determine the incidence of OC after transplantation. 
Study Desing: We analyzed the prevalence and risk factors of OC in a group of 500 RTPs (307 men, 193 women, 
mean age 53.63 years) and 501 HC subjects (314 men, 187 women, mean age 52.25 years). Demographic and 
pharmacological data were recorded for all subjects. Incident cases of OC were ascertained retrospectively from 
outpatient clinical records only in the RTP group. 
Results: The prevalence of OC was 7.4% in RTPs compared with 4.19% in HC (P<0.03). The most frequent type 
of OC in the two groups was denture stomatitis. Statistical association was found between OC and age, mycophe-
nolate mofetil dose and blood levels, dentures and tobacco. The multiple logistic regression model only chose for 
denture variable. According to the outpatient clinical records, 24 RTPs suffered OC during the first moth post-
transplant. Severe lesions affecting the oral cavity and pharynx appeared in 79% of the OC cases. 
Conclusions: This study shows a lower prevalence of OC in RTPs than previous reports. Denture stomatitis was 
the most frequent OC prevalence form described in RTPs. Severe candidiasis is more frequent in the immediate 
posttransplant period. The presence of denture is an important risk factor of OC. These results emphasise the 
importance of adequate pre- and post-transplant oral health and denture cleaning and adjustment is recommended 
for these subjects to prevent this infection.
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Introduction
Solid-organ transplantation is a globally accepted pro-
cedure for patients with irreversible organ failure. This 
therapy is associated with different side-effects and the 
necessary immunosuppression leads to increased rates of 
infection, malignancy, and other complications (1-3).
Candidal infections are particularly prevalent after organ 
transplantation (4,5). Candida species can trigger infec-
tions of the bloodstream and esophagus as well as other 
organs in RTPs (6,7). Oral candidiasis (OC) can predis-
pose such patients to esophageal candidiasis, an invasive 
form of infection with significant morbidity (5,8). 
Previous studies have shown that RTPs have consid-
erably higher prevalence of OC than healthy controls 
(HCs), and this condition is the most frequent oral in-
fection in RTPs, with a prevalence ranging between 
7.7% and 46.7% (8-13). 
The transition of Candida from commensal to patho-
gen is often associated with predisposing factors. The 
systemic factors promoting OC in RTPs are immuno-
suppressant dose, diabetes mellitus, retransplantation, 
prolonged antibiotic use, leukopenia, xerostomic drugs, 
previous cytomegalovirus and/or human herpes virus 
6 infections, and old age (2,6,14-18). Local factors ei-
ther alter the mucosal barrier or diminish the quality 
or quantity of saliva to promote OC; they include poor 
oral hygiene, poor oral and dental condition, presence 
of dirty or poorly fitting dentures, antibiotic and/or local 
corticosteroid treatment, smoking, and physical and/or 
chemical trauma (18).
Recently, we observed that OC is the most frequent oral 
lesion in both RTPs and HCs (19). However, studies of 
the potential risk factors and predictors for this condi-
tion in RTPs are lacking. In addition, some studies sug-
gested that oral infections, including candidiasis, are 
more severe in the immediate posttransplantation pe-
riod (4,5), but cross-sectional studies of OC in RTPs did 
not support this finding (8-13). In this sense, a longitu-
dinal design would be more reliable to analyze whether 
OC is more common in the immediate posttransplanta-
tion period and study its associated factors. Therefore, 
the aims of this study were to analyze the prevalence of 
and risk factors for OC in RTPs compared with age- and 
gender-matched HCs as well as determine the incidence 
of OC after transplantation. 
Material and Methods
-Study Population
Five hundred patients who underwent kidney transplan-
tation between February 1989 and March 2007 were 
recruited from the outpatient Renal Transplant Clinic 
of Hospital 12 de Octubre in Madrid (307 men, 193 
women; mean age = 53.63 ± 13.42 years, age range = 
19–95 years; mean posttransplantation period = 59.66 
± 55.81 months, posttransplantation range = 1–330 
months). HCs were recruited from the Julio Morate 
Health Center in Madrid (314 men, 187 women; mean 
age = 52.25 ± 15, age range = 20–93 years). The study 
was approved by the ethics committee of Hospital 12 
de Octubre and written informed consent was obtained 
from all subjects. 
All the HCs routinely received medical treatment for 
conditions such as hypertension, diabetes, or weight 
control, but none sought treatment for any oral mucosal 
disorder. HCs were excluded if they received a trans-
plant, underwent immunosuppressant and/or corticos-
teroid therapy, or had renal diseases. Neither the RTPs 
nor the HCs received antibiotic, antifungal, or antiviral 
therapy one month before the assessment.
-Clinical Assessment
The oral mucosa and lips of all subjects were examined 
clinically by one investigator (R.M.L.P). The clinical 
diagnosis of candidiasis followed the criteria by Hol-
mstrup and Axell (20), and the definitive diagnosis was 
supported by a positive response to antifungal treat-
ment, positive candidal culture, and presence of can-
didal hyphae in stained smears. Incident cases of OC 
only in the RTPs were ascertained retrospectively from 
outpatient clinical records. The clinical diagnosis of OC 
in these cases was based on the clinical impression and 
supported by a positive response to therapy.
-Analyzed Variables
The data of both study populations were reviewed with 
regard to gender, age, diabetic history, antidepressant 
treatment, smoking habits, alcohol consumption, and 
presence of dentures. The time since transplantation, 
immunosuppressive treatment, and immunosuppres-
sant dose were reviewed only for the RTPs. Further, 
hematologic studies were performed only for the RTPs, 
including testing for immunosuppressant blood levels, 
neutrophil and eosinophil counts, and hemoglobin and 
creatinine levels. These studies were conducted on the 
same day as the oral examination.
The subjects were asked about their smoking habits 
and current alcohol consumption. A smoking habit was 
measured in terms of cigarettes smoked per day. One 
cigar was assumed to be equal to four cigarettes. The 
intake of alcoholic beverages was expressed in units of 
alcohol per day (one unit = approximately 10 gm alco-
hol, half pint of beer, one small glass of wine, or one 
measure of spirits/hard liquor). 
-Statistical Analysis
Statistical analysis was performed by using SPSS ver-
sion 19.0 for Windows (IBM-SPSS, Inc., Chicago, IL). 
Differences between continuous variables and categori-
cal variables were assessed by Student’s t-test and chi-
square test, respectively. Multiple logistic regression 
analysis was conducted to explore the associations 
between OC and selected clinical variables. Variables 
were included in the model if they were predictors of 
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the outcome (p < 0.05). The final model included group 
(RTPs/HCs), age, mycophenolate mofetil (MMF) dose 
and blood level, smoking habit, and presence of den-
tures. P < 0.05 was considered significant.
Results
The clinical data of the study populations are presented 
in table 1. Overall, 4.8% of the men and 7.4% of the 
women had OC (P < 0.12). The subjects with OC were 
significantly older than those without OC (60.24 ± 12.44 
vs. 52.49 ± 14.23, P < 0.0001). The presence of OC was 
statistically associated with smoking (P < 0.05) and 
the presence of dentures (P < 0.0001). OC appeared 
in 85.2% of the RTPs and 61.1% of the HCs who wore 
acrylic dentures as well as in 14.8% of the RTPs and 
22.2% of the HCs who wore metallic dentures. 
The different immunosuppressant schedules for the 
RTPs are listed in table 2. We did not find a statistical 
Variables RTP (n=500) HC (n=501) p 
Gender   0.68 
Male 307 (61.4%) 314 (62.7%) 
Female 193 (38.6%) 187 (37.3%) 
Age (years) 53.63 ± 13.42 52.25 ± 15 0.12
Active smokers 103 (20.6%) 142 (28.3%) 0.004 
Tobacco consumption (cigarettes/day) 2.49 ± 6.06 4.03 ± 8.31 0.001 
Smoking history 122 (24.4%) 49 (9.78%) 0.0001 
Alcohol 72 (14.4%) 121 (24.2%) 0.0001 
Alcohol consumption (dose/day) 0.23 ± 0.66 0.40 ± 0.86 0.001 
Diabetic patients 85 (17%) 16 (3.2%) 0.0001 
Insulin dependent diabetes 57 (11.4%) 3 (0.6%) 
Non insulin dependent diabetes 28 (5.6%) 13 (2.6%) 
Patients with dentures 135 (27%) 100 (20%) 0.002 
Acrylic denture 82 (16.4%) 46 (9.2%) 
Metallic denture 48 (9.6%) 43 (8.6%) 
Acrylic and metallic dentures 5 (1%) 11 (2.2%) 
Antidepressant treatment 66 (13.2%) 28 (5.6%) 0.004 
Immunosuppressive regimen Frequency 
Pred + FK + MMF 186 (37.2%) 
Pred + CsA + MMF 72 (14.4%) 
Pred + CsA 45 (9%) 
Pred + FK 34 (6.8%) 
Pred + FK + Aza 26 (5.2%) 
Pred + CsA + Aza 23 (4.6%) 
Pred + CsA + Siro 16 (3.2%) 
CsA 15 (3%) 
FK + MMF 13 (2.6%) 
Pred + Siro 12 (2.4%) 
CsA + MMF 12 (2.4%) 
Pred + FK + Siro 10 (2%) 
Pred + Siro + MMF 9 (1.8%) 
FK 8 (1.6%) 
Pred + Aza 6 (1.2%) 
Pred + MMF 4 (0.8%) 
MMF 3 (0.6%) 
Siro + MMF 2 (0.4%) 
FK + Siro 2 (0.4%) 
CsA + Aza 1 (0.2%) 
CsA + Siro 1 (0.2%) 
Table 1. Subject variables and risk factors and the differences between RTPs and HC.
Table 2. Immunosuppressive regimen of RTPs of study.
Pred, prednisolone; FK, FK-506; MMF, mycophenolate 
mofetil; CsA, cyclosporine A; Aza, azathioprine; Siro, si-
rolimus.
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association between the presence of OC and the differ-
ent immunosuppressant regimens (P < 0.83). The main 
regimens were prednisolone, tacrolimus, and MMF 
(35.13%); prednisolone, cyclosporine A (CsA), and 
MMF (16.22%); prednisolone and CsA (10.81%); and 
CsA alone (8.10%). 
Table 3 shows the mean immunosuppressant doses and 
blood levels as well as the number of RTPs adminis-
tered these immunosuppressants. We found a statistical 
association between the presence of OC and the dose 
and blood level of MMF (P < 0.017 and P < 0.001, re-
spectively). The RTPs with OC had received a mean 
MMF dose of 1177.08 ± 558.92 mg and had a mean 
Variables Mean  ±  SD Subjects
Pred dose (mg) 6.91 ± 6.39 443 
CsA dose (mg) 160.39 ± 61.79 187 
FK dose (mg) 5.26 ± 2.96 279 
Siro dose (mg)  2.40 ± 1.20 52 
MMF dose (mg) 977.08 ± 427.99 301 
Aza dose (mg) 77.23 ± 26.23 56 
CsA blood level (ng/ml) 154.11 ± 62.74 187 
FK blood level (ng/ml) 8.52 ± 2.86 279 
Siro blood level (ng/ml) 8.69 ± 3.06 40 
MMF blood level (ng/ml) 2.38 ± 2.04 112 
PMN e (%) 1.64 ± 1.21 500 
PMN n (%) 63.61 ± 11.05 500 
Hemoglobin (g/dl) 13.89 ± 1.92 500 
Creatinine (ng/ml) 1.58 ± 1.23 500 
Time since transplant (months) 59.66 ± 55.81 500 
MMF blood level of 4.37 ± 3.65 ng/ml. The mean MMF 
dose and blood level in the RTPs without OC were 960 
± 411.45 mg and 2.18 ± 1.71 ng/ml, respectively.
We found no statistical association between the pres-
ence of OC and the time since transplantation, dose 
and blood levels of the other immunosuppressants (i.e., 
apart from MMF), and the pharmacologic and hemato-
logic variables in the RTPs. We did not find a statistical 
association between the presence of OC and diabetic 
history, antidepressant treatment, and alcohol consump-
tion, in the RTPs and HCs. 
The RTPs had significantly higher prevalence of OC 
than the HCs (7.4% vs. 4.19%, P < 0.03). Denture sto-
matitis was the most frequent form of OC in RTPs and 
HCs (5.4% and 3.6%, respectively), followed by angular 
cheilitis (1.6% and 0.2%) and pseudomembranous can-
didiasis (0.4% and 0.4%).
The odds ratio (OR) and 95% confidence interval (CI) in 
the final multiple logistic regression model chose only 
the presence of dentures as a significant variable. The 
RTPs and HCs who wore dentures were more prone to 
OC. Further, OC was more frequent in the RTPs who 
wore acrylic dentures (OR, 28.45; 95% CI, 13.64–59.34; 
P = 0.000) than in those who wore acrylic and metallic 
dentures (OR, 17.45; 95% CI, 4.29–70.88; P = 0.000) or 
metallic dentures alone (OR, 9.33; 95% CI, 3.77–23.09; 
P = 0.000).
Table 4 provides information regarding the incident 
cases of OC in the RTPs. According to the outpatient 
clinical records, 24 RTPs (4.8%) suffered from OC in 
the first posttransplantation month, and 79.2% of these 
OC cases involved severe candidal lesions affecting the 
oral cavity and anterior pharyngeal pillars. 
Discussion
In this study, we found higher prevalence of OC in the 
RTPs than in the HCs (7.4% vs. 4.19%). This result con-
forms to that reported by Dongari-Bagtzoglou et al. 
(8), a 7.7% OC prevalence in RTPs, suggests that the 
prevalence of OC in RTPs may be much lower than that 
previously reported (9.4–46.7%) (9-13). The difference 
may be attributable to variations in population charac-
teristics, including the time after transplantation, im-
munosuppressant regimens, sample size, demographic 
causes, and overall health status of the populations ex-
amined. Importantly, immunosuppressive treatments 
have changed in the recent years. There have been 
Table 3. Mean ± standard deviation of inmunosuppresive drugs doses taken by 
the RTPs and laboratory test. 
Mean ± SD, mean ± standar desviation; Pred, prednisolone; FK, FK-506; MMF, 
mycophenolate mofetil; CsA, cyclosporine A; Aza, azathioprine; Siro, siroli-
mus.
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dramatic shifts in baseline immunosuppression with 
increased use of induction agents and the nearly uni-
versal replacement of azathioprine by MMF. Further, 
tacrolimus use has increased whereas CsA use has fall-
en (21). Mammalian-target-of-rapamycin inhibitors are 
usually used nowadays as well (22). These changes in 
immunosuppressant protocols may be responsible for 
the discrepancies observed among different studies. 
It is important to point out that OC is frequently asymp-
tomatic (18). No patient with OC in our study had symp-
toms during diagnosis, justifying the importance of 
regular oral examinations, because OC can predispose 
in RTPs to esophageal candidiasis (5,8). 
Infections in RTPs use to follow a predictable pattern 
in the posttransplantation period. This period is di-
vided into three phases: the first posttransplantation 
month, 1–6 months posttransplantation, and 6 months 
posttransplantation and beyond. During the first post-
transplantation month, the types of infection are simi-
lar to those seen postoperatively in immunocompetent 
patients. The causative organisms include Candida spe-
cies, herpes simplex virus, and nosocomial bacteria. 
Thereafter, up to 6 months posttransplantation, recipi-
ents of solid-organ transplants have the maximum dys-
function of cellular immunity. Infections in this period 
are usually produced by intracellular or opportunistic 
pathogens, although OC and recurrent intraoral herpet-
ic infections are also frequently seen. In the third phase 
after transplantation, the risk of infection varies and 
depends on the clinical course during the previous two 
phases and the state of immunosuppression (16).
We collected the clinical records of the RTPs since 
their transplantation. Twenty-four RTPs suffered from 
OC in the first posttransplantation month, 19 of whom 
had large candidal lesions affecting the oral cavity and 
pharynx. This follow-up has not been conducted previ-
ously and such severe cases of OC were not observed in 
other studies of RTPs (8-13). This finding may be be-
Gender Age TST(days) Type of candidiasis Location Treatment IS treatment Risk factors
M 35 7 Erythematous Oropharyngeal Nystatin Pred+TAC+MMF Hemolytic anemia 
M 41 14 Erythematous-pseudomembranous Oropharyngeal Nystatin Pred+TAC+MMF 
ID diabetes 
Acrylic denture 
M 50 20 Angular cheilitis Corner of the mouth Nystatin Pred+TAC+MMF Acrylic denture 
F 33 14 Pseudomembranous Oropharyngeal Nystatin Pred+TAC+MMF ID diabetes Leukopenia 
M 68 7 Erythematous Oropharyngeal Fluconazole Pred+CsA ID diabetes 
M 48 7 Erythematous Oropharyngeal Fluconazole Pred+CsA Acrylic denture 
F 60 14 Pseudomembranous Intraoral Fluconazole Pred+TAC+MMF Acute graft rejection 
M 53 14 Erythematous Oropharyngeal Nystatin Pred+TAC+Aza Acrylic denture 
M 67 7 Pseudomembranous Oropharyngeal Nystatin Pred+TAC+MMF NID diabetes 
M 50 30 Angular cheilitis Corner of the mouth Nystatin Pred+TAC+MMF Acrylic denture 
M 47 7 Pseudomembranous Oropharyngeal Nystatin Pred+CsA+MMF NID diabetes 
F 59 7 Erythematous-pseudomembranous Oropharyngeal Nystatin Pred+MMF+Siro NID diabetes 
F 73 14 Erythematous Oropharyngeal Nystatin + Fluconazole Pred+Siro Acrylic denture 
M 40 7 Pseudomembranous Intraoral Fluconazole Pred+TAC+MMF  
F 73 7 Pseudomembranous Oropharyngeal Nystatin Pred+CsA  
F 55 15 Angular cheilitis Corner of the mouth Nystatin Pred+CsA+MMF Acrylic denture 
M 67 7 Pseudomembranous Oropharyngeal Nystatin Pred+TAC+MMF Acute graft rejection 
F 69 14 Erythematous Oropharyngeal Nystatin Pred+TAC Acrylic denture 
F 67 7 Erythematous Oropharyngeal Fluconazole Pred+TAC+MMF NID diabetes 
M 41 14 Pseudomembranous Oropharyngeal Nystatin Pred+TAC+MMF ID diabetes 
M 67 7 Pseudomembranous Oropharyngeal Nystatin Pred+TAC+MMF Acrylic denture 
F 56 14 Erythematous Oropharyngeal Nystatin Pred+TAC+MMF Metallic denture 
M 46 7 Erythematous Oropharyngeal Nystatin Pred+TAC Acrylic denture 
F 64 14 Erythematous Oropharyngeal Nystatin Pred+TAC+MMF NID diabetes 
Table 4. Incident cases of OC in RTPs.
M = male; F = female; TST = time since transplant; IS = immunosuppressive treatment; Pred = prednisolone; TAC = Tacrolimus; MMF = 
mycophenolate mofetil; CsA = cyclosporine A; Aza = azathioprine; Siro = sirolimus; ID diabetes = insulin-dependent diabetes; NID diabetes 
= non-insulin-dependent diabetes.
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cause of severe immunosuppression in the immediate 
posttransplantation period, increasing the risk of OC in 
these patients. 
The relationship between the type of immunosuppres-
sant and the prevalence of OC remains controversial. 
Spolidorio et al. (23) showed that RTPs receiving a CsA-
based immunosuppressant regimen have higher sali-
vary levels of Candida species than those treated with 
FK-506. These findings are quite striking because the 
immunosuppressive potential of FK-506 is higher than 
that of CsA. However, we were unable to find any rela-
tionship between the prevalence of OC and the different 
immunosuppressant protocols, similar to the study by 
Dongari-Bagtzoglou et al. (8).
Immunosuppressants commonly administered to RTPs, 
such as corticosteroids, adversely affect all aspects of im-
munity. Moreover, certain antiproliferative medications, 
such as MMF and azathioprine, can trigger neutropenia, 
an important predisposing factor for candidiasis (8). In 
fact, Anees et al. (24) suggested that the use of MMF is 
associated with a higher rate of clinically apparent OC 
than the immunosuppressant regimens without this drug. 
In our study, we observed a significant relationship be-
tween the presence of OC and high doses and blood lev-
els of MMF. Although immunosuppressants seemingly 
elevate the risk of OC, significant associations of their 
doses and blood levels with higher risk of OC (apart from 
the MMF dose and blood level) were not demonstrated 
in this and other studies (8-12). This lack of association 
could be explained by the need for pharmacologically 
homogeneous RTP populations to achieve statistically 
significant results. It would be interesting to analyze the 
presence of OC in uniform groups of RTPs receiving dif-
ferent immunosuppressant regimens.
Diabetes has been associated with a higher tendency for 
OC (25,26). However, Dongari-Bagtzoglou et al. (8) did 
not find any relationship between the presence of dia-
betes and Candida colonization, colony-forming units, 
and titers in the oral cavity of recipients of kidney or 
heart transplants and HCs. Similarly, we found no rela-
tionship between the presence of OC and diabetic his-
tory. This result may be attributable to the fact that the 
patients with diabetes in our study had good blood glu-
cose control. Some studies have shown that candidiasis 
occurs in conditions of poor blood glucose control (25-
27). Studies to ascertain the relationships between the 
blood glucose levels and the prevalence and severity of 
OC in RTPs are desirable. 
Golecka et al. (28) showed that patients with transplants 
who wear dentures are more likely to suffer from denture 
stomatitis and angular cheilitis than HCs with dentures. 
In our study, the clinical forms of OC associated with 
removable dentures were more frequent in the RTPs 
than in the HCs. Further, the RTPs who wore dentures 
were more likely to develop OC. The high prevalence of 
denture stomatitis in such patients highlights the need 
for adequate pre transplantation and posttransplantation 
oral health as well as denture cleaning and adjustment 
to prevent this infection. 
Tobacco is a local risk factor that favors the development 
of OC. In our study, we observed that tobacco was as-
sociated with OC. This may be due to the decrease the 
amount of saliva produced and the alteration of the anti-
bacterial properties by tobacco habit increasing the colo-
nization of the oral cavity by Candida albicans (29).
In conclusion, we have shown that RTPs have signifi-
cantly higher prevalence of OC than HCs, although the 
prevalence is lower than that previously reported. Den-
ture stomatitis is the most frequent form of OC in RTPs, 
followed by angular cheilitis and pseudomembranous 
candidiasis. Severe candidiasis is more frequent in the 
immediate posttransplantation period. The presence of 
dentures is a major risk factor for OC. Our results empha-
size the importance of adequate pretransplantation and 
posttransplantation oral health and regular denture clean-
ing and adjustment to prevent this infection in RTPs.
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